Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT1 | P17948 | 19/20 | 0.64 |
| ▸ | KDR | P35968 | 19/20 | 0.64 |
| ▸ | PDGFRB | P09619 | 11/20 | 0.50 |
| ▸ | KIT | P10721 | 10/20 | 0.50 |
| ▸ | CIT | O14578 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | HLA-A | P04439 | 1/20 | 0.44 |
| ▸ | CSF1R | P07333 | 1/20 | 0.44 |
| ▸ | RET | P07949 | 1/20 | 0.44 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.44 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.44 |
| ▸ | FLT4 | P35916 | 1/20 | 0.44 |
| ▸ | FRK | P42685 | 1/20 | 0.44 |
| ▸ | CDK8 | P49336 | 1/20 | 0.44 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.44 |
| ▸ | STK3 | Q13188 | 1/20 | 0.44 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.44 |
| ▸ | MAP3K19 | Q56UN5 | 1/20 | 0.44 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.44 |
| ▸ | MAP3K20 | Q9NYL2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4817664 | 0.95 | FLT1 (0.62) | FLT1KDRPDGFRBKITCIT | |
| SCHEMBL14293515 | 0.83 | FLT1 (0.57) | FLT1KDRPDGFRBKITCIT | |
| SCHEMBL6607456 | 0.82 | FLT1 (0.46) | FLT1KDRPDGFRBKITCIT | |
| SCHEMBL6587711 | 0.82 | SHMT2 (0.54) | FLT1KDRPDGFRBKIT | |
| SCHEMBL905518 | 0.80 | FLT1 (0.59) | FLT1KDRPDGFRBKITCIT | |
| SCHEMBL30773496 | 0.80 | FLT1 (0.59) | FLT1KDRPDGFRBKITCIT | |
| SCHEMBL6588404 | 0.79 | FLT1 (0.53) | FLT1KDRPDGFRBKITCIT | |
| SCHEMBL4810051 | 0.77 | FLT1 (0.79) | FLT1KDRPDGFRBKITCIT | |
| SCHEMBL6607498 | 0.77 | TSHR (0.56) | FLT1KDRPDGFRBKITCIT | |
| SCHEMBL3754268 | 0.76 | FLT1 (0.39) | FLT1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7329660-B2 | Phthalazine derivatives for treating inflammatory diseases | NOVARTIS AG (CH) | 2008-02-12 | — | — | US | disclosed |
| US-7329660-B2 | Phthalazine derivatives for treating inflammatory diseases | NOVARTIS AG (CH) | 2008-02-12 | — | — | US | disclosed |
| US-7329660-B2 | Phthalazine derivatives for treating inflammatory diseases | NOVARTIS AG (CH) | 2008-02-12 | — | — | US | disclosed |
| US-20060217388-A1 | Phthalazine derivatives for treating inflammatory diseases | BOLD GUIDO | 2006-09-28 | — | — | US | disclosed |
| EP-1165085-B1 | PHTHALAZINE DERIVATIVES FOR TREATING INFLAMMATORY DISEASES | NOVARTIS AG (CH) | 2006-06-14 | — | — | EP | disclosed |
| CN-1221262-C | Phthalazine derivatives for the treatment of inflammatory diseases | NOVARTIS AG (CH) | 2005-10-05 | — | — | CN | disclosed |
| CN-1660840-A | Phthalazine derivatives for treating inflammatory diseases | NOVARTIS AG (CH) | 2005-08-31 | — | — | CN | disclosed |
| US-20050176711-A1 | Phthalazine derivatives for treating inflammatory diseases | BOLD GUIDO (CH) | 2005-08-11 | — | — | US | disclosed |
| US-6911440-B2 | Phthalazine derivatives for treating inflammatory diseases | NOVARTIS AG (CH) | 2005-06-28 | — | — | US | disclosed |
| US-20040142934-A1 | Phthalazine derivatives for treating inflammatory diseases | BOLD GUIDO (CH) | 2004-07-22 | — | — | US | disclosed |
| US-6686347-B2 | RHEUMATIC DISEASES; ANALGESICS; ENZYME INHIBITORS | NOVARTIS AG (CH) | 2004-02-03 | — | — | US | disclosed |
| US-20030013718-A1 | Phthalazine derivatives for treating inflammatory diseases | NOVARTIS AG (CH) | 2003-01-16 | — | — | US | disclosed |
| CN-1367695-A | Phthalazine derivatives for the treatment of inflammatory diseases | NOVARTIS AG (CH) | 2002-09-04 | — | — | CN | disclosed |
| EP-1165085-A1 | PHTHALAZINE DERIVATIVES FOR TREATING INFLAMMATORY DISEASES | Novartis AG (CH) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000059509-A1 | PHTHALAZINE DERIVATIVES FOR TREATING INFLAMMATORY DISEASES | NOVARTIS AG (CH) | 2000-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013718-A1 | Phthalazine derivatives for treating inflammatory diseases | FLT1, KDR, FFAR2 | FLT1 1/4885KDR 2/4885PDGFRB 65/4885 |
| US-20060217388-A1 | Phthalazine derivatives for treating inflammatory diseases | KDR, NR2E3, FLT1 | FLT1 3/4885KDR 1/4885PDGFRB 85/4885 |
| US-20040142934-A1 | Phthalazine derivatives for treating inflammatory diseases | KDR, FLT1, TIE1 | FLT1 2/4885KDR 1/4885PDGFRB 41/4885 |
| US-20050176711-A1 | Phthalazine derivatives for treating inflammatory diseases | FLT1, FLT4, KDR | FLT1 1/4885KDR 3/4885PDGFRB 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.